Extended Data Fig. 5: Absence of B.1.351 spike-specific antibodies in humans receiving B.1.351-matched booster as a third-dose vaccine.
From: Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines
a, Scheme of immunizations and blood draw. Participants received two doses of 100 μg of mRNA-1273 one month apart and were boosted with 50 μg of the indicated mRNA vaccine at least six months later. Sera were collected one month after the third dose (n = 5). 1273, mRNA-1273; 351, mRNA-1273.351; 211, mRNA-1273.211 (Wuhan-1–B.1.351 bivalent vaccine). b, Antibody binding to Wuhan-1 (top) and B.1.351 (bottom) spike proteins of sera pre-cleared with empty beads (no Dp), B.1.351 spike-loaded beads (B.1.351 Dp), or Wuhan-1 spike-loaded beads (Wuhan-1 Dp) (connecting lines represent sera from the same individual; dotted lines show the LOD; values at the LOD are plotted slightly below the LOD for visualization). c, Percentages of Wuhan-1 (top) and B.1.351 (bottom) spike-specific antibodies (horizontal lines and numbers at the top denote median values). Pie charts illustrate the fraction of type-specific and cross-reactive IgG in each group. d, Neutralizing activity of pre-cleared sera against Wuhan-1 (top) and B.1.351 (bottom) pseudoviruses (numbers above data points indicate the GMT; fractions indicate the numbers of individuals with detectable neutralization by type-specific antibodies). Pie charts illustrate the fraction of neutralization mediated by type-specific and cross-reactive antibodies. Serum samples with an NT50 below the LOD after pre-clearing with empty beads (no Dp) were not used in pie chart analyses. c, Kruskal-Wallis ANOVA with Dunn’s post-test (P values are shown).